Meet the Experts Behind the Navigating NAMs in Drug Development Webinar

Thank you for tuning in to our webinar, Navigating the Shift from Animal Testing to NAMs in Drug Development.

 
As scientific advances and evolving FDA expectations accelerate the move toward modern, human-relevant methods, sponsors must determine how New Approach Methodologies (NAMs) fit within their specific development programs. Whether you are evaluating alternatives to traditional animal studies or exploring how modeling can strengthen your evidence strategy, our experts are here to help.
 
Continue the conversation with the speakers from our webinar. Combining expertise in nonclinical safety, toxicology, regulatory strategy, pharmacometrics, and Model-Informed Drug Development (MIDD), they help sponsors identify practical opportunities to integrate NAMs while addressing scientific and regulatory requirements.
 

Whether your team is planning a new program or reassessing an existing development strategy, we’re here to discuss challenges such as:

• Identifying where NAMs could reduce, refine, or replace animal studies
• Aligning nonclinical safety and toxicology plans with evolving FDA expectations
• Integrating NAM-generated evidence with MIDD and pharmacometric approaches
• Preparing for pre-IND meetings and other regulatory interactions
• Using quantitative modeling to strengthen evidence and guide development decisions

Meet the Experts

William Salminen, Ph.D., DABT, PMP Vice President, Toxicology and Clinical Pharmacology/Pharmacometrics

Angelean Hendrix, Ph.D. Vice President, Pharmacometrics and MIDD

Let’s discuss your development goals and explore how NAMs, toxicology strategy, and MIDD could support your program. Complete the form to have your questions answered by our experts.